

## **Pharmacy Drug Policy Checklist**

POLICY NAME Symdeko (tezacaftor-ivacaftor) POLICY # 2640P

## Criteria

Coverage Criteria	
	Documented diagnosis of cystic fibrosis with
	Documentation that member is homozygous for the F508del mutation OR member has at least one mutation in the CFTR gene that is responsive to Symdeko
	Age 6 years of age or older
	Prescribed by a provider specializing in the treatment of cystic fibrosis
	Review of chart notes documenting diagnosis and confirming that patient has met all of the above requirements for treatment with Symdeko by both a pharmacist and medical director